Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Everest MedicinesSTU:6HN -3.57%51 Days Inventory is 9.90 as of Dec. 2025, which is 94% below its 10-year median of 163.47. GuruFocus rates STU:6HN with a GF Score™ of 51/100 and a GF Value™ of €33.53 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 638 Biotechnology companies, Everest Medicines ranks better than 97.02% on this metric.
The historical rank and industry rank for Everest Medicines's Days Inventory or its related term are showing as below:
STU:6HN'
s Days Inventory Range Over the Past 10 Years
Min: 12.68 Med: 163.47 Max: 7130.54
Current: 12.68
During the past 8 years, Everest Medicines's highest Days Inventory was 7130.54. The lowest was 12.68. And the median was 163.47.
STU:6HN's Days Inventory is ranked better than 97.02% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs STU:6HN: 12.68
Everest Medicines's Days Inventory
declined
from Dec. 2024 (34.44) to Dec. 2025 (9.90).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Everest Medicines's Inventory Turnover for the
six
months ended in Dec. 2025 was 18.44.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Everest Medicines's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.02.
Everest Medicines (STU:6HN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Everest Medicines's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Everest Medicines's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Everest Medicines Days Inventory Related Terms
Everest Medicines Days Inventory Historical Data
* Premium members only.
The historical data trend for Everest Medicines's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6HN vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Everest Medicines's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's Days Inventory distribution charts can be found below:
* The bar in red indicates where Everest Medicines's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Everest Medicines (STU:6HN) has a Days Inventory of 9.90 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Everest Medicines and its competitors. This is 94% below median its historical median of 163.47. Over the past decade, Everest Medicines' Days Inventory has ranged from 12.68 to 7,130.54. According to the industry distribution chart, Everest Medicines ranks #19 out of 638 companies in the Biotechnology industry, placing it in the top 3%.
Is Everest Medicines' Days Inventory too high?
Everest Medicines' current Days Inventory of 9.90 is 94% below median its 10-year median of 163.47. Over the past 10 years, this metric has ranged from a low of 12.68 to a high of 7,130.54. The Biotechnology industry median Days Inventory is 183.20. Everest Medicines' value of 9.90 is 94.6% below this industry median. Based on the distribution chart, Everest Medicines ranks #19 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Everest Medicines has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Everest Medicines ranks #19 out of 638 companies for Days Inventory. This places Everest Medicines in the top 3% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.20. Everest Medicines' value of 9.90 is 94.6% below this benchmark. Historically, Everest Medicines' own Days Inventory has ranged from 12.68 to 7,130.54 over the past decade. While the company's 10-year median is 163.47 vs. the industry median of 183.20, Everest Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Everest Medicines's current Days Inventory of 9.90 is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Everest Medicines and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Everest Medicines's current Days Inventory is 9.90, which is 94% below median its own 10-year median of 163.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (STU:6HN) is currently considered Possible Value Trap. The stock's GF Value™ is €33.53, compared to a current price of €2.70 — trading 91.9% below its estimated fair value. The current Days Inventory is 9.90, which is 94% below median its 10-year median of 163.47 and 94.6% below the Biotechnology industry median of 183.20. Everest Medicines' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Everest Medicines (STU:6HN), the current Days Inventory is 9.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Medicines (STU:6HN) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued.
The current stock price of €2.70 is trading 91.9% below its estimated GF Value™ of €33.53.
GuruFocus considers Everest Medicines to be Possible Value Trap.
Key valuation signals for STU:6HN:
Days Inventory: 9.90 (94% below median its 10-year median of 163.47)
GF Value™: €33.53 vs. price of €2.70 (91.9% below fair value)
Industry Position: 94.6% below the Biotechnology median (#19 of 638)
No single metric tells the full story. See the STU:6HN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
51GF Score
Get the complete analysis for STU:6HN
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6HN has been successfully added to your 
